Wee J Chng

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma
    Wee J Chng
    Comprehensive Cancer Center and Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Genes Chromosomes Cancer 45:1111-20. 2006
  2. ncbi Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
  3. ncbi Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    Wee J Chng
    Department of Hematology-Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
    Blood 108:2755-63. 2006
  4. ncbi Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities
    Esteban Braggio
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ, USA
    Mod Pathol 25:651-60. 2012
  5. ncbi The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 111:1603-9. 2008
  6. ncbi Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications
    Wee J Chng
    Department of Hematology Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ, USA
    Blood 113:635-45. 2009
  7. ncbi Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology-Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
  8. ncbi Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics
    Wee J Chng
    Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Lymphoma Myeloma 6:200-7. 2005
  9. ncbi Genomics in multiple myeloma: biology and clinical implications
    Wee J Chng
    Division of Hematology-Oncology, Mayo Clinic Scottsdale, Johnson Research Building, 13400 E Shea Blvd, AZ 85259, USA
    Pharmacogenomics 6:563-73. 2005
  10. ncbi Cell lines of hyperdiploid myeloma, are we there yet?
    Wee J Chng
    Br J Haematol 140:579-80; author reply 580-1. 2008

Detail Information

Publications16

  1. ncbi Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma
    Wee J Chng
    Comprehensive Cancer Center and Division of Hematology Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Genes Chromosomes Cancer 45:1111-20. 2006
    ..The development of these genetic aberrations is thus highly ordered and undoubtedly of biological relevance. Within this framework, we propose a model of genetic evolution in H-MM...
  2. ncbi Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
    ..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients...
  3. ncbi Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    Wee J Chng
    Department of Hematology-Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
    Blood 108:2755-63. 2006
    ..Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue...
  4. ncbi Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities
    Esteban Braggio
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ, USA
    Mod Pathol 25:651-60. 2012
    ..Elucidation of the genetic alterations contributing to the pathogenesis of these lymphomas may guide to design-specific therapeutic approaches...
  5. ncbi The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 111:1603-9. 2008
    ..Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis...
  6. ncbi Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications
    Wee J Chng
    Department of Hematology Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ, USA
    Blood 113:635-45. 2009
    ..In conclusion, MALT subgroups with distinct pathologic features defined by distinct groups of deregulated genes were identified. These genes could represent novel diagnostic and therapeutic targets...
  7. ncbi Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology-Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  8. ncbi Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics
    Wee J Chng
    Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Clin Lymphoma Myeloma 6:200-7. 2005
    ..This review will summarize the important prognostic factors identified to date, how they can be used to identify patients at high risk, and their clinical utility in relation to treatment optimization at diagnosis...
  9. ncbi Genomics in multiple myeloma: biology and clinical implications
    Wee J Chng
    Division of Hematology-Oncology, Mayo Clinic Scottsdale, Johnson Research Building, 13400 E Shea Blvd, AZ 85259, USA
    Pharmacogenomics 6:563-73. 2005
    ..Genomics will have an important role to play in all of these goals...
  10. ncbi Cell lines of hyperdiploid myeloma, are we there yet?
    Wee J Chng
    Br J Haematol 140:579-80; author reply 580-1. 2008
  11. ncbi Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events
    Wee J Chng
    Blood 109:3610-1. 2007
  12. ncbi Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
    ..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents...
  13. ncbi Tandem bone marrow transplantation in multiple myeloma
    Wee J Chng
    N Engl J Med 350:1466-7; author reply 1466-7. 2004
  14. ncbi Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications
    Natalia Gonzalez Paz
    Department of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 109:1228-32. 2007
    ....
  15. ncbi Multiple myeloma presenting with complex cranial nerve palsies
    Andrea Wong
    J Neurooncol 74:217-8. 2005
  16. ncbi Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies
    Wee J Chng
    Department of Haematology Oncology, National University Hospital, Singapore, Republic of Singapore
    Clin Diagn Lab Immunol 11:168-73. 2004
    ..This platform should be used for future studies into the effects of age, sex, and race on lymphocyte subsets...